Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

The Journal of Managed Care & Specialty Pharmacy is a premier publication in the realm of health policy and pharmaceutical science, dedicated to enhancing the understanding and practices surrounding managed care systems and specialty medications. Published by ACAD MANAGED CARE PHARMACY, this journal boasts an impressive Q1 ranking in both Pharmaceutical Science and Pharmacy, underscoring its significance in advancing professional discourse and research in these critical areas. With a focus on innovative care strategies and patient-centered approaches, it aims to share impactful research, reviews, and opinions that shape the future of health policy and pharmaceutical practices. The journal is available in an open access format, ensuring that vital information is universally accessible to researchers, practitioners, and policymakers alike. With its inception in 2014 and an ongoing commitment to excellence through 2024, the journal is firmly established as a leading resource within its field, making it essential reading for professionals dedicated to improving managed care and specialty pharmacy solutions.

Journal of Young Pharmacists is a distinguished peer-reviewed journal published by INPHARM ASSOCIATION in collaboration with PHCOG NET. With an ISSN of 0975-1483 and an E-ISSN of 0975-1505, this journal serves as a vital platform for disseminating pioneering research in the field of pharmacology and toxicology. Although coverage in Scopus was discontinued in 2018, the journal continues to be important in educating future pharmacists and advancing the discipline, evident from its ranking in the 29th percentile among general pharmacology journals. The Journal of Young Pharmacists seeks to bridge the gap between theoretical knowledge and practical application, encouraging young researchers, professionals, and students to contribute their insights and findings. The journal emphasizes innovative approaches and contemporary issues relevant to the pharmaceutical sciences, making it an invaluable resource for anyone involved in this dynamic field.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

Journal of Comparative Effectiveness Research is a leading academic journal dedicated to the evaluation of healthcare interventions and practices, published by Becaris Publishing. Since transitioning to a fully Open Access model in 2023, the journal has expanded its accessibility to a global audience of researchers, healthcare professionals, and policy makers. With a focus on comparative effectiveness in health policy, it has achieved a notable ranking of #132 out of 310 in the Scopus category for Medicine and Health Policy, placing it in the 57th percentile for scholarly impact. Operating from the United Kingdom, the journal encompasses research from 2012 to 2024 and firmly establishes itself in the academic landscape as a Q2 journal in the Health Policy category as of 2023. By disseminating high-quality, evidence-based research, the Journal of Comparative Effectiveness Research plays a vital role in informing clinical practice and health policy decision-making, making it an essential resource for those dedicated to improving health outcomes.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

Journal of Health Economics and Outcomes Research, published by COLUMBIA DATA ANALYTICS, LLC, serves as a vital resource in the field of health policy and public health, providing researchers, professionals, and students with open access to pioneering studies since its inception in 2013. With its ISSN and E-ISSN both listed as 2327-2236, this journal aims to disseminate high-quality research that evaluates healthcare efficiency and outcomes. Situated in the United States, at 145 Hudson St., Suite 205, New York, NJ 10013, it has made significant strides in its category quartiles within the 2023 rankings, achieving Q2 status in both Health Policy and Public Health, Environmental and Occupational Health. Furthermore, it maintains respectable Scopus rankings, with a percentile of 51st in health policy and 49th in public health. By bridging gaps in health economics and policy discourse, the journal stands as an indispensable platform for advancing knowledge and fostering innovation in health services research.